Alaunos Therapeutics Files 8-K

TL;DR

Alaunos Therapeutics filed a routine 8-K on Aug 20 for an Aug 19 event. No major news.

AI Summary

Alaunos Therapeutics, Inc. filed an 8-K on August 20, 2025, reporting an event on August 19, 2025. The filing is categorized under 'Other Events' and does not specify any significant financial transactions or corporate changes beyond the routine reporting requirement.

Why It Matters

This filing indicates Alaunos Therapeutics, Inc. is adhering to its reporting obligations with the SEC, which is standard for publicly traded companies.

Risk Assessment

Risk Level: low — The filing is a standard 8-K for 'Other Events' and does not disclose any material non-public information or significant corporate actions.

Key Players & Entities

• Alaunos Therapeutics, Inc. (company) — Registrant
• August 19, 2025 (date) — Date of earliest event reported
• August 20, 2025 (date) — Date of report
• Delaware (jurisdiction) — State of incorporation
• 501 E. Las Olas Blvd., Suite 300 Fort Lauderdale, FL 33301 (address) — Principal executive offices

FAQ

Key Financial Figures

• $0.001 — ch registered Common Stock, par value $0.001 per share TCRT The Nasdaq Stock Mar
• $2.5 million — require, respectively, a minimum of (i) $2.5 million in stockholders' equity, (ii) $35 milli
• $35 million — 5 million in stockholders' equity, (ii) $35 million in market value of listed securities, o
• $500,000 — et value of listed securities, or (iii) $500,000 of net income from continuing operation
• $2.06 m — ompany reported stockholders' equity of $2.06 million, which did not satisfy the Rule 5
• $3.66 m — 025, evidencing stockholders' equity of $3.66 million, the Listing Qualifications staff

Filing Documents

• tcrt-20250819.htm (8-K) — 53KB
• 0000950170-25-110484.txt ( ) — 157KB
• tcrt-20250819.xsd (EX-101.SCH) — 26KB
• tcrt-20250819_htm.xml (XML) — 5KB

01. Other Events

Item 8.01. Other Events. On August 19, 2025, Alaunos Therapeutics, Inc. (the "Company") was notified by Listing Qualifications staff of The Nasdaq Stock Market LLC ("Nasdaq") that the Company has regained compliance with the continued listing requirements of the Nasdaq Capital Market. As previously disclosed, on April 7, 2025, the Company received a notice from the Listing Qualifications staff of Nasdaq (the "Notice") stating that the Company did not comply with the continued listing requirements of the Nasdaq Capital Market under Nasdaq Listing Rules 5550(b)(1), 5550(b)(2), or 5550(b)(3), which require, respectively, a minimum of (i) $2.5 million in stockholders' equity, (ii) $35 million in market value of listed securities, or (iii) $500,000 of net income from continuing operations. In its Annual Report on Form 10-K for the year ended December 31, 2024, the Company reported stockholders' equity of $2.06 million, which did not satisfy the Rule 5550(b)(1) requirement. The Notice had no immediate effect on the Company's listing, and the Company submitted a compliance plan within 45 calendar days, as permitted under Nasdaq rules. Based on the Company's Quarterly Report on Form 10-Q for the period ended June 30, 2025, evidencing stockholders' equity of $3.66 million, the Listing Qualifications staff of Nasdaq has determined that the Company complies with the Nasdaq Listing Rules and has confirmed the matter is now closed.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Alaunos Therapeutics, Inc. Date: August 20, 2025 By: /s/ Holger Weis Name: Holger Weis Title: Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR